TrialPharmaceutical statistics2023

A Bayesian phase I/II design to determine subgroup-specific optimal dose for immunotherapy sequentially combined with radiotherapy.

Beibei Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.